


## Curriculum Vitae

<b>Name</b>	<b>Yoshiaki Nakamura</b>	
<b>Current Position &amp; Affiliation</b>	<b>Staff physician in Translational Research Support Section, Translational Research Management Division, Clinical Research Support Office / Department of Gastrointestinal Oncology, National Cancer Center Hospital East</b>	
<b>Country</b>	<b>Japan</b>	

### Educational Background

Apr 2003-Mar 2009 M.D., Osaka University

Apr 2015-Mar 2018 Ph.D., Keio University

### Professional Experience

Apr 2009-Mar 2011 Resident in Tenri Hospital

Apr 2011-Mar 2014 Trainee in Department of Medical Oncology,  
Kameda General Hospital

Apr 2014-Mar 2019 Trainee in Department of Gastroenterology and  
Gastrointestinal Oncology,  
National Cancer Center Hospital East

Jan 2015-Jan 2016 Division of Epigenomics,  
National Cancer Center Research Institute

Apr 2019-present Staff physician in Translational Research Support Section,  
Translational Research Management Division, Clinical  
Research Support Office / Department of Gastrointestinal  
Oncology,  
National Cancer Center Hospital East

## Professional Organizations

Mar 13th, 2009	Full Medical License (Japan) #483528
Sep 2012	Board Certified Member of the Japanese Society of Internal Medicine # 101-1239156
Apr 2017	Diplomate, Subspecialty Board of Medical Oncology, JSMO # 1600028

## Main Scientific Publications

1. Hasegawa H, Taniguchi H, **Nakamura Y**, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. *Cancer science* 2020 doi: 10.1111/cas.14693 [published Online First: 2020/10/20]
2. **Nakamura Y**, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JJ, Yoshino T. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. *Nature medicine* 2020;26(12):1859-64. doi: 10.1038/s41591-020-1063-5 [published Online First: 2020/10/07]
3. **Nakamura Y**, Shitara K. Development of circulating tumour DNA analysis for gastrointestinal cancers. *ESMO Open* 2020;5(Suppl 1) doi: 10.1136/esmoopen-2019-000600 [published Online First: 2020/08/25]
4. Kawazoe A, Fukuoka S, **Nakamura Y**, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, Sato A, Kuwata T, Shitara K. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. *Lancet Oncol* 2020;21(8):1057-65. doi: 10.1016/S1470-2045(20)30271-0 [published Online First: 2020/06/27]

5. Sasaki A, **Nakamura Y\***, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K. Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. *Gastric Cancer* 2020 doi: 10.1007/s10120-020-01058-4 [published Online First: 2020/03/18]

**\*Co-first author**

6. Moro H, Hattori N, **Nakamura Y**, Kimura K, Imai T, Maeda M, Yashiro M, Ushijima T. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways. *Gastric Cancer* 2020;23(1):105-15. doi: 10.1007/s10120-019-01010-1 [published Online First: 2019/09/27]
7. Willis J, Lefterova MI, Artyomenko A, Kasi PM, **Nakamura Y**, Mody K, Catenacci DVT, Fakhri M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasz A, Kopetz S, Lee J, Odegaard JI. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. *Clin Cancer Res* 2019 doi: 10.1158/1078-0432.CCR-19-1324 [published Online First: 2019/08/07]
8. Sasaki A, **Nakamura Y\***, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. *Gastric Cancer* 2019;22(4):793-802. doi: 10.1007/s10120-018-00922-8 [published Online First: 2019/01/11]

**\*Co-first author**

9. **Nakamura Y**, Yamanaka T, Shitara K. Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?", by Marino, Elisabetta et al. *Ann Surg Oncol* 2019;26(3):919-20. doi: 10.1245/s10434-018-07142-5 [published Online First: 2019/01/06]
10. **Nakamura Y**, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. *Ann Surg Oncol* 2019;26(2):465-72. doi: 10.1245/s10434-018-7063-8 [published Online First: 2018/11/21]

11. **Nakamura Y**, Sawada K, Fujii S, Yoshino T. HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naive, HER2-amplified metastatic colorectal cancer. *ESMO Open* 2019;4(3):e000530. doi: 10.1136/esmooopen-2019-000530 [published Online First: 2019/07/30]
  12. Sawada K, **Nakamura Y**, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. *Clin Colorectal Cancer* 2018;17(3):198-205. doi: 10.1016/j.clcc.2018.05.006 [published Online First: 2018/06/06]
  13. **Nakamura Y**, Yoshino T. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. *Oncologist* 2018;23(11):1310-18. doi: 10.1634/theoncologist.2017-0621 [published Online First: 2018/04/28]
  14. Matsumoto H, Sasaki A, **Nakamura Y**, Kawazoe A, Kuboki Y, Okinaka K, Shitara K. Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer. *Case Rep Oncol* 2018;11(1):228-33. doi: 10.1159/000488313 [published Online First: 2018/05/29]
  15. **Nakamura Y**, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T, Ushijima T. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. *Cancer Lett* 2017;402:100-09. doi: 10.1016/j.canlet.2017.05.017 [published Online First: 2017/06/04]
-